Axsome Therapeutics, Inc. (AXSM)
Health Care · CNS specialty pharmaceuticals · Nasdaq
A fully integrated biopharmaceutical company developing innovative CNS treatments, with three FDA-approved commercial products and a deep pipeline of novel candidates.
What Axsome Therapeutics, Inc. does
Axsome Therapeutics is a fully integrated biopharmaceutical company focused on developing innovative medicines for central nervous system (CNS) conditions. The company has three FDA-approved commercial products: AUVELITY® for major depressive disorder, SUNOSI® for excessive daytime sleepiness, and SYMBRAVO® for acute migraine treatment. Axsome generates revenue from product sales and royalties, with total revenues of $638.5 million in 2025 (66% annual growth), and is advancing a deep pipeline of novel product candidates in early- to late-stage development.
Themes: ["Major depressive disorder (MDD) treatment"]
Fundamentals
- Price$233.80 as of 2026-07-10 close
- Market cap$12.0B as of 2026-07-12
- 1-year return+111.1% as of 2026-07-10 close
- Net margin-26.6% as of 2026-07-12
- Gross margin+92.6% as of 2026-07-12
- ROE-260.0% as of 2026-07-12
- Debt / equity3.61 as of 2026-07-12
- Revenue growth (YoY)+63.9% as of 2026-07-12
- Revenue CAGR (3y)+133.7% SEC XBRL
- Beta0.72 as of 2026-07-12
Key risks (from latest filing)
["Dependence on market acceptance of three commercial products (AUVELITY, SUNOSI, SYMBRAVO) and ability to maintain market share against competitors"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.